PHATHOM PHARMACEUTICALS, INC. Paid-in-Kind Interest
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Paid-in-Kind Interest of $3.48 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2025-10-30
- PHATHOM PHARMACEUTICALS, INC. paid-in-kind interest for the quarter ending 2025-09-30 was $1.18M, a 15.93% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. paid-in-kind interest for the quarter ending 2025-06-30 was $1.16M, a 28.63% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. paid-in-kind interest for the quarter ending 2025-03-31 was $1.14M, a 41.56% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. paid-in-kind interest for the quarter ending 2024-12-31 was $1.05M, a 16.91% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. paid-in-kind interest for fiscal 2024 was $3.77M, a 5.36% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. paid-in-kind interest for fiscal 2023 was $3.58M, a 2.84% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. paid-in-kind interest for fiscal 2022 was $3.48M, a 251.92% increase from fiscal 2021.
- PHATHOM PHARMACEUTICALS, INC. paid-in-kind interest for fiscal 2021 was $990.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.34M derived: sum of 2 quarters · filed 2025-10-30 | $3.48M 10-Q · filed 2025-10-30 | $4.53M derived: sum of 4 quarters · filed 2025-10-30 |
| 2025-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.30M 10-Q · filed 2025-08-07 | $3.35M derived: sum of 3 quarters · filed 2025-08-07 | $4.37M derived: sum of 4 quarters · filed 2025-10-30 |
| 2025-03-31 | $1.14M 10-Q · filed 2025-05-01 | $2.19M derived: sum of 2 quarters · filed 2025-05-01 | $3.21M derived: sum of 3 quarters · filed 2025-10-30 | $4.11M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $2.07M derived: sum of 2 quarters · filed 2025-10-30 | $2.97M derived: sum of 3 quarters · filed 2025-10-30 | $3.77M 10-K · filed 2025-03-06 |
| 2024-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.92M derived: sum of 2 quarters · filed 2025-10-30 | $2.72M 10-Q · filed 2025-10-30 | $3.62M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $901.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.71M 10-Q · filed 2025-08-07 | $2.61M derived: sum of 3 quarters · filed 2025-08-07 | $3.52M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $806.00K 10-Q · filed 2025-05-01 | $1.71M derived: sum of 2 quarters · filed 2025-05-01 | $2.62M derived: sum of 3 quarters · filed 2025-05-01 | $3.51M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $899.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.81M derived: sum of 2 quarters · filed 2025-03-06 | $2.71M derived: sum of 3 quarters · filed 2025-03-06 | $3.58M 10-K · filed 2025-03-06 |
| 2023-09-30 | $912.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.81M derived: sum of 2 quarters · filed 2024-11-07 | $2.68M 10-Q · filed 2024-11-07 | $3.57M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $895.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | $1.77M 10-Q · filed 2024-08-08 | $2.66M derived: sum of 3 quarters · filed 2024-08-08 | $3.54M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $877.00K 10-Q/A · filed 2024-06-14 | $1.77M derived: sum of 2 quarters · filed 2024-06-14 | $2.65M derived: sum of 3 quarters · filed 2024-06-14 | $3.51M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $890.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $1.77M derived: sum of 2 quarters · filed 2024-06-14 | $2.64M derived: sum of 3 quarters · filed 2024-06-14 | $3.48M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $881.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.75M derived: sum of 2 quarters · filed 2023-11-09 | $2.59M 10-Q · filed 2023-11-09 | $3.45M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $865.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.71M 10-Q · filed 2023-08-10 | $2.57M derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | $848.00K 10-Q · filed 2023-05-10 | $1.71M derived: sum of 2 quarters · filed 2023-05-10 | ||
| 2021-12-31 | $860.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $990.00K 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $130.00K 10-Q/A · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |